ERBB2 and breast cancer: We further examined ER, PR, Ki‐67, and HER2 status for the risk of advanced stage vs early stage breast cancer, and found that negative expression of PR (OR = 1.43, 95% CI: 1.02‐2.02), positive expression of HER2 (OR = 1.83, 95% CI: 1.29‐2.59), and the expression of Ki67 higher than 14% (OR = 1.58, 95% CI: 1.00‐2.50) increased the odds of breast cancer at advanced stage in multivariate‐adjusted analyses.